Related Experiment Video
Updated: Jul 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Aliskiren: the first direct renin inhibitor for hypertension
Anton H van den Meiracker1, A H Jan Danser
1Division of Vascular Pharmacology and Metabolism, Room EE1418b, Department of Internal Medicine, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, Netherlands.
Abstract:
Aliskiren is the first member of a novel class of antihypertensive agents, the renin inhibitors, that has been approved by the US Food and Drug Administration for the treatment of hypertension. This review discusses its potential differences compared with existing renin-angiotensin-aldosterone system blockers, focusing also on the inactive precursor of renin, prorenin, and the recently discovered (pro)renin receptor. The review summarizes the findings from all clinical trials with aliskiren published so far, and provides an overview of the safety and tolerability of the new drug.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hypertension IV: Drug Therapy and Lifestyle Modifications
Antihypertensive Drugs: Potassium-Sparing Diuretics
